All In Biotech

Drug Trial Radar · NCT05634746

24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)

Fluticasone Propionate Oral Disintegrating Tablet Formulation in Eosinophilic Esophagitis: A Randomized, Double-blind, Placebo-Controlled 24-Week Induction Study of APT-1011, Followed by a Single-arm Open-label Extension, in Adult Subjects With Eosinophilic Esophagitis

Last checked: Nov 20, 2026Latest source record: Aug 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 218 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

218

Actual

Start

Dec 29, 2022

Primary completion

Aug 12, 2024

Study completion Aug 12, 2024

Sponsor

Lead sponsor
Ellodi Pharmaceuticals, LPIndustry
Sponsor type
Industry
First posted
Dec 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 24-week randomized, double-blind, placebo-controlled induction study of APT-1011 in adults (≥18 years old) with eosinophilic esophagitis (EoE) followed by a single-arm, open-label extension. This study will evaluate the efficacy and safety of APT-1011 3 mg administered HS (hora somni, at bedtime) for the induction of response to treatment (symptomatic and histologic) over 24 weeks. The open-label extension will continue to evaluate long-term safety in subjects who consent to continue on open-label treatment with APT-1011.

Conditions

  • Eosinophilic Esophagitis

Interventions

  • APT-1011Drug

    APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient. Other Names: fluticasone propionate

  • Placebo oral tabletDrug

    Placebo orally disintegrating tablet. Other Names: PBO

  • EsophagogastroduodenoscopyProcedure

    Esophagogastroduodenoscopy (EGD) is a test that involves an endoscope, a lighted camera on the end of a tube, that is passed down a subject's throat to visualize their esophagus

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Histological Remission (Co-Primary Outcome Measure)Time frame: Week 24
  2. Complete Symptomatic Response (Co-Primary Outcome Measure)Time frame: Week 24

Locations

60 sites in 2 countries. Site status is shown where the registry gives one.

  • Digestive Health Specialists

    Dothan, Alabama

  • East View Medical Research LLC

    Mobile, Alabama

  • Premier Allergy Asthma and Immunology

    Scottsdale, Arizona

  • Del Sol Research Management, LLC.

    Tucson, Arizona

  • Preferred Research Partners, Inc.

    Little Rock, Arkansas

  • Arkansas Gastroenterology

    North Little Rock, Arkansas

  • Om Research LLC

    Camarillo, California

  • Providence Facey Medical Foundation

    Mission Hills, California

  • United Medical Doctors

    Murrieta, California

  • TriWest Research Associates, LLC

    San Diego, California

  • Precision Research Institute, LLC

    San Diego, California

  • Peak Gastroenterology Associates

    Colorado Springs, Colorado

  • Western States Clinical Research, Inc.

    Wheat Ridge, Colorado

  • Medical Research Center of Connecticut, LLC

    Hamden, Connecticut

  • Nature Coast Clinical Research

    Inverness, Florida

  • I.H.S Health, LLC

    Kissimmee, Florida

  • Endoscopic Research Inc

    Orlando, Florida

  • Revival Clinical Research

    Orlando, Florida

  • Gastroenterology Associates of Central Georgia, LLC

    Macon, Georgia

  • GI Alliance - Glenview

    Glenview, Illinois

  • GI Alliance - Gurnee

    Gurnee, Illinois

  • Deaconess Clinic Allergy

    Evansville, Indiana

  • Gastroenterology Health Partners, PLLC

    New Albany, Indiana

  • Velocity Clinical Research, Inc.

    Overland Park, Kansas

  • MGG Group Co., Inc., Chevy Chase Clinical Research

    Chevy Chase, Maryland

  • Gastro Center of Maryland, LLC

    Columbia, Maryland

  • Velocity Clinical Research, Inc.

    Rockville, Maryland

  • Boston Specialists

    Boston, Massachusetts

  • Clinical Research Institute of Michigan, LLC

    Chesterfield, Michigan

  • Henry Ford Health System

    Novi, Michigan

  • Clinical Research Institute of Michigan, LLC

    Troy, Michigan

  • Gastroenterology Associates of Western Michigan

    Wyoming, Michigan

  • MNGI Digestive Health, P.A.

    Plymouth, Minnesota

  • Clinical Research Professionals

    Chesterfield, Missouri

  • Bozeman Health

    Bozeman, Montana

  • Advanced Research Institute

    Reno, Nevada

  • New Mexico Clinical Research & Osteoporosis Center, Inc.

    Albuquerque, New Mexico

  • New York Gastroenterology Associates

    New York, New York

  • UNC Clinical and Translational Research Center (CTRC)

    Chapel Hill, North Carolina

  • Charlotte Gastroenterology & Hepatology, PLLC

    Charlotte, North Carolina

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.